Mozenavir
Structural formula | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||
Non-proprietary name | Mozenavir | |||||||||
other names |
[4 R (4 α , 5 α , 6 β , 7 β )] - hexahydro-5,6-dihydroxy-1,3-bis [((3-aminophenyl) methyl) -4,7-bis (phenylmethyl) -2 H -1,3-diazepin-2-one] ( IUPAC ) |
|||||||||
Molecular formula | C 33 H 36 N 4 O 3 | |||||||||
External identifiers / databases | ||||||||||
|
||||||||||
Drug information | ||||||||||
Drug class | ||||||||||
properties | ||||||||||
Molar mass | 536.68 g · mol -1 | |||||||||
safety instructions | ||||||||||
|
||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Mozenavir (also DMP-450 ) is a drug from the group of HIV protease inhibitors that was developed by Gilead Sciences . As the active ingredient showed no significant advantages over conventional HIV protease inhibitors, development was discontinued.
pharmacology
Mozenavir binds very tightly to the active site of the HIV protease. This prevents the processing of viral polyprotein precursors.
literature
Analytics:
- RD Vickery, MB Maurin, in: Journal of Pharmaceutical and Biomedical Analysis 1999 , 20 , 385-388.
- Grubb MF, Robinson CA, White SJ, Krauthauser CL, Shum L., in: Journal of Chromatography B 1996 , 678 , 303-308.
Synthesis:
- M. Patel, LT Bacheler et al., In: Bioorg. Med. Chem. Lett. 1998 , 8 , 823-828.
Pharmacology:
- PYS Lam, Y.Ru, PK Jadhav, PE Aldrich et al., In: J. Med. Chem. 1996 , 39 , 3514-3525.
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.